FDA Approves Olaparib Tablets for Maintenance Treatment in Ovarian Cancer
On August 17, 2017, the U.S. Food and Drug Administration granted regular approval to olaparib tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
Olaparib Does Not Decrease Quality-of-Life in Patients With Ovarian Cancer
Patients with platinum-sensitive relapsed (PSR) serous ovarian cancer (SOC) have poor survival outcomes, with the median progression-free survival (PFS) after chemotherapy less than six months in many patients. Based on results from the SOLO2 study that found that maintenance olaparib after response to chemotherapy resulted in a significant improvement in PFS compared to placebo (median PFS = 19.1 versus 5.5 months) in patients with germline BRCA mutation PSR SOC (hazard ratio [HR] = 0.30; 95% CI = 0.22–0.41; p < 0.0001), researchers assessed the impact of health-related quality-of-life (HRQOL). The researchers presented the study at the ASCO Annual Meeting.
FDA Approves Niraparib for Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
On March 27, 2017, the U.S. Food and Drug Administration (FDA) approved niraparib, a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
FDA Approves Rucaparib for Advanced Ovarian Cancer
FDA Recommends Against Ovarian Cancer Screening Tests
Maintenance Treatment May Prolong Progression-Free Survival in Ovarian Cancer
ONS Strategic Sponsor Approximately 15 percent of woman with ovarian cancer have a BRCA mutation and every year, many patients with ovarian cancer are not tested for a BRCA mutation. Family history and age are poor predictors of BRCA status in ovarian cancer patients, which is why it is so important for all women with ovarian cancer to be tested. BeBRCAware is a movement to raise awareness about the importance of genetic testing for a BRCA mutation in ovarian cancer.